Secure CheckoutPersonal information is secured with SSL technology.
Free ShippingFree global shipping
No minimum order.
Hands-on Approach for the Conduct of Nonclinical Studies: A Manual for Anticipating and Avoiding Potential Problems focuses on practical approaches to real-life challenges faced during nonclinical studies, providing insights into the anticipation of potential problems and solutions to problems which may arise, thus saving time, money and resources. The book outlines Good Laboratory Practice in detail and includes regulatory guidelines, communication, stakeholder information and case studies. It is essential reading for study directors/technical coordinators, quality assurance personnel, all technical staff and project managers. In addition, it offers guidance for those new to the area, while also acting as a reference for senior researchers.
- Includes an introduction to Good Laboratory Practice (GLP) scenarios and related regulations
- Explains aspects of study directorship, including documentation, document review, implementation and execution of preclinical studies
- Provides a detailed account of the responsibilities of each stakeholder (technical, managerial, sponsor) within the study and how timely they need to act to seamlessly move a project
Study directors, toxicologists working in nonclinical drug development, toxicology professors and students, regulatory toxicologists, medical and veterinary scientists
- The Stakeholders: The federal agencies aka the audience, the sponsors, and the management
2. What is GLP?
3. Role and responsibilities of the sponsor, study director, and study coordinator
4. Study Director and Study Coordinator: Review of Test Article information and standardization of formulation procedure
5. Dose volume, analytical and bioanalytical method set-up for supporting nonclinical studies
6. Conduct of rodent and non-rodent MTD/DRF studies
7. Conduct of repeat dose toxicity studies in rodent and non-rodent species
8. Conduct of Genotoxicity studies (in vitro and in vivo)
9. Conduct of Safety Pharmacology studies
10. Conduct of DART program
11. Conduct of Carcinogenicity Studies
- No. of pages:
- © Academic Press 2020
- 1st June 2029
- Academic Press
- Paperback ISBN:
Dr. Dandekar has over 15 years of experience working in academia, agrochemical and pharmaceutical research and development. He has been involved in the completion of multiple successful IND enabling programs supporting clinical development and leading to strong regulatory submissions of New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for various biotech/pharmaceutical companies (Sponsor’s). He earned his zoology doctorate from the Maharaja Sayajirao University of Baroda, India. Dr. Dandekar has given expert lectures at a variety of institutions and published multiple scholarly articles
Founder, Blue River Drug Development, LLC, USA
Dr. Limaye has written over a dozen papers and book chapters and has worked as a postdoctoral fellow at the University of Pittsburgh School of Medicine and the University of Kansas Medical Center. She earned her PhD from University of Louisiana at Monroe in Toxicology.
Principal Scientist, MRIGlobal, USA
Elsevier.com visitor survey
We are always looking for ways to improve customer experience on Elsevier.com.
We would like to ask you for a moment of your time to fill in a short questionnaire, at the end of your visit.
If you decide to participate, a new browser tab will open so you can complete the survey after you have completed your visit to this website.
Thanks in advance for your time.